Merck KGaA (MRK) Rating Reiterated by JPMorgan Chase & Co.
Merck KGaA (FRA:MRK)‘s stock had its “neutral” rating restated by research analysts at JPMorgan Chase & Co. in a research report issued on Wednesday.
A number of other equities analysts have also recently commented on the stock. Sanford C. Bernstein set a €105.00 ($122.09) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, August 9th. Barclays set a €70.00 ($81.40) price target on shares of Merck KGaA and gave the stock a “sell” rating in a research note on Friday, August 24th. UBS Group set a €115.00 ($133.72) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, August 9th. Deutsche Bank set a €91.00 ($105.81) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Monday, August 13th. Finally, Commerzbank set a €100.00 ($116.28) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. Merck KGaA has an average rating of “Hold” and an average target price of €98.71 ($114.78).
MRK stock traded down €0.14 ($0.16) during midday trading on Wednesday, reaching €87.30 ($101.51). The company had a trading volume of 199,591 shares. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.